Effects of Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa on Sleep Dysfunction in People With Parkinson's

Background: The study objective was to assess whether 24-hour/day continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa (LDp/CDp) improves Parkinson ’s Disease Sleep Scale-2 (PDSS-2) subdomains in people with Parkinson’s (PwP). The PDSS-2 provides a Total Score (TS) and subdomain scores for: Motor Symptoms at Night (MS), Parkinson’s Disease Symptoms at Night (PDS), and Disturbed Sleep (DS). A double-blind 12-week phase 3 trial of LDp/CDp C SCI versus levodopa-carbidopa immediate-release (LD/CD-IR) oral tablets (NCT04380142) suggested improvements in the intention-to-treat (ITT) population PDSS-2 TS.
Source: Parkinsonism and Related Disorders - Category: Neurology Authors: Source Type: research